The UK and US have hammered out a key bilateral deal that will ensure no levies on UK drug exports being sold in the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has agreed to raise expenditure on pharmaceuticals through the public health system. This pledge guarantees that duties on these crucial exports will stay at zero for a timeframe of the next three years.
This development comes after earlier warnings to hike duties on patented pharmaceutical imports, with increases mentioned as high as 100%.
"This agreement with the Britain strengthens the worldwide climate for new treatments and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," an announcement declared.
Trade Significance
Drugs represent one of the the United Kingdom's biggest goods shipped to the United States, which is clearly the biggest destination for major UK drugmakers.
Trade data indicate that in the year prior to the third quarter, the UK shipped pharmaceutical products worth billions to the US. This figure made up nearly one-fifth of all goods exports in that span.
"This agreement secures work, increases funding and facilitates the UK to become a global hub for biotech and pharma," a minister remarked.
Specific NHS Changes
The pact includes several specific commitments from the UK:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it considers new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double total health service expenditure on drugs from 0.3% of Gross Domestic Product to 0.6% over the following ten-year period.
- Rebate Cap: The amount manufacturers must return to the NHS to prevent overspending will be limited at 15%. In the past, rebates exceeded 20%.
Industry Background
The deal follows a long-running tension between the drug companies and the UK government over drug pricing and approval rates.
This friction were exacerbated by claims that American customers were paying several times more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or abandoned, while major investments have been announced toward American operations.
A senior figure acknowledged that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had decreased as a proportion of its overall budget over the last ten years.
